Crossmark Global Holdings, Inc. Gilead Sciences, Inc. Transaction History

Crossmark Global Holdings, Inc.

$5.61 Billion
Q3 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 531,479 shares of GILD stock, worth $49.2 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares

531,479

Previous 497,098 6.92%

Holding current value

$49.2 Million

Previous $34.1 Million 30.65%

% of portfolio

0.79%

Previous 0.65%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	BUY	$66.59 - $83.99 $2.29 Million - $2.89 Million	34,381 Added 6.92%	531,479 $44.6 Million
Q2 2024 Jul 29, 2024	BUY	$63.15 - $72.88 $736,139 - $849,562	11,657 Added 2.4%	497,098 $34.1 Million
Q1 2024 May 13, 2024	SELL	$71.58 - $87.29 $1.91 Million - $2.33 Million	-26,656 Reduced 5.21%	485,441 $35.6 Million
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $252,122 - $285,912	-3,441 Reduced 0.67%	512,097 $41.5 Million
Q3 2023 Nov 08, 2023	BUY	$73.94 - $80.67 $234,833 - $256,207	3,176 Added 0.62%	515,538 $39.2 Million
Q2 2023 Jul 31, 2023	BUY	$76.01 - $86.7 $3.3 Million - $3.76 Million	43,381 Added 9.25%	512,362 $39.4 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $9.35 Million - $10.6 Million	120,885 Added 34.73%	468,981 $38.9 Million
Q4 2022 Jan 19, 2023	BUY	$62.32 - $89.47 $963,591 - $1.38 Million	15,462 Added 4.65%	348,096 $29.9 Million
Q3 2022 Nov 01, 2022	BUY	$59.54 - $68.01 $228,871 - $261,430	3,844 Added 1.17%	332,634 $20.5 Million
Q2 2022 Jul 29, 2022	BUY	$57.72 - $65.01 $391,745 - $441,222	6,787 Added 2.11%	328,790 $20.3 Million
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $5.32 Million - $6.67 Million	91,879 Added 39.93%	322,003 $19.1 Million
Q4 2021 Jan 10, 2022	BUY	$64.88 - $73.64 $2.23 Million - $2.53 Million	34,412 Added 17.58%	230,124 $16.7 Million
Q3 2021 Oct 21, 2021	BUY	$67.69 - $73.03 $10.3 Million - $11.1 Million	151,654 Added 344.21%	195,712 $13.7 Million
Q3 2021 Oct 13, 2021	SELL	$67.69 - $73.03 $10.3 Million - $11.1 Million	-151,608 Reduced 77.48%	44,058 $1.46 Million
Q2 2021 Jul 21, 2021	BUY	$63.47 - $69.35 $614,199 - $671,099	9,677 Added 5.2%	195,666 $13.5 Million
Q1 2021 Apr 15, 2021	BUY	$60.0 - $68.46 $10,620 - $12,117	177 Added 0.1%	185,989 $12 Million
Q4 2020 Jan 14, 2021	SELL	$56.65 - $64.55 $275,092 - $313,454	-4,856 Reduced 2.55%	185,812 $10.8 Million
Q3 2020 Oct 08, 2020	SELL	$62.1 - $78.08 $477,859 - $600,825	-7,695 Reduced 3.88%	190,668 $12 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $936,007 - $1.09 Million	-12,939 Reduced 6.12%	198,363 $15.3 Million
Q1 2020 Apr 28, 2020	SELL	$62.63 - $80.22 $251,208 - $321,762	-4,011 Reduced 1.86%	211,302 $15.8 Million
Q4 2019 Feb 06, 2020	BUY	$61.62 - $67.78 $281,233 - $309,347	4,564 Added 2.17%	215,313 $14 Million
Q3 2019 Oct 09, 2019	SELL	$62.51 - $69.0 $351,556 - $388,056	-5,624 Reduced 2.6%	210,749 $13.4 Million
Q2 2019 Jul 09, 2019	SELL	$61.87 - $69.38 $136,732 - $153,329	-2,210 Reduced 1.01%	216,373 $14.6 Million
Q1 2019 May 02, 2019	BUY	$62.53 - $70.05 $386,060 - $432,488	6,174 Added 2.91%	218,583 $14.2 Million
Q4 2018 Jan 31, 2019	BUY	$60.54 - $79.0 $534,749 - $697,807	8,833 Added 4.34%	212,409 $13.3 Million
Q3 2018 Nov 08, 2018	BUY	$71.28 - $78.92 $36,994 - $40,959	519 Added 0.26%	203,576 $15.7 Million
Q2 2018 Jul 31, 2018	SELL	$64.88 - $75.68 $35,684 - $41,624	-550 Reduced 0.27%	203,057 $14.4 Million
Q1 2018 Apr 16, 2018	SELL	$72.84 - $88.8 $1.62 Million - $1.97 Million	-22,187 Reduced 9.83%	203,607 $15.4 Million
Q4 2017 Feb 05, 2018	BUY	$71.15 - $83.52 $287,303 - $337,253	4,038 Added 1.82%	225,794 $16.2 Million
Q3 2016 Oct 25, 2017	BUY	N/A	221,756	221,756 $18 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Gilead Sciences, Inc. Transaction History